2 papers
stat.AP2026
Evaluation of Minimal Residual Disease as a Surrogate for Progression-Free Survival in Hematology Oncology Trials: A Meta-Analytic Review
Jane She, Xiaofei Chen, Malini Iyengar +1
Traditional health authority approval for oncology drugs is based on a clinical benefit endpoint, or a valid surrogate. In 1992 the FDA created the Accelerated Approval pathway to…
stat.ME2025
An optimal dynamic treatment regime estimator for indefinite-horizon survival outcomes
Jane She, Matthew Egberg, Michael R. Kosorok
We propose a new method in indefinite-horizon settings for estimating optimal dynamic treatment regimes for time-to-event outcomes. This method allows patients to have different nu…